Literature DB >> 11568722

[Personal experience with the endoscopic treatment of pancreatic pseudocysts. Long-term results and analysis of prognostic factors].

G D De Palma1, G Galloro, A Puzziello, S Masone, G Diamantis, G Persico.   

Abstract

BACKGROUND: The aim of this study was to assess the safety and utility of endoscopic treatment of pancreatic pseudocysts. Prognostic factors for the outcome of endoscopic drainage were assessed in a prospective analysis.
METHODS: Forty-nine consecutive symptomatic patients were included in the study. Transmural drainage was used in 30 patients and transpapillary drainage in 19 patients.
RESULTS: Successful drainage was achieved in 27/30 (90%) of patients after transmural drainage and in 16/19 (84.2%) patients after transpapillary drainage. Twelve (24.5%) patients had complications; 2 patients had bleeding, 2 had mild pancreatitis, 8 had cyst infection, in relation to the presence of necrosis (5 patients) or stent clogging (3 patients). Nine patients (20.9%) had recurrence of pseudocyst. Endoscopic drainage was a definitive treatment in 37 out of 49 (75.5%) patients (median follow-up: 25.9 months). Presence of necrosis was the only significant prognostic factor for infectious complication.
CONCLUSIONS: Endoscopic drainage provides a successful and safe minimally invasive approach to the management of pancreatic pseudocysts.

Entities:  

Mesh:

Year:  2001        PMID: 11568722

Source DB:  PubMed          Journal:  Minerva Chir        ISSN: 0026-4733            Impact factor:   1.000


  2 in total

1.  Endoscopic management of pancreatic pseudocysts and walled-off pancreatic necrosis: A two-decade experience.

Authors:  Shyam S Sharma; Bir Singh; Mukesh Jain; Sudhir Maharshi; Sandeep Nijhawan; Bharat Sapra; Ashok Jhajharia
Journal:  Indian J Gastroenterol       Date:  2016-02-29

2.  Differential treatment and early outcome in the interventional endoscopic management of pancreatic pseudocysts in 27 patients.

Authors:  Uwe Will; Conrad Wegener; Kai-Ivo Graf; Igor Wanzar; Thomas Manger; Frank Meyer
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.